AVDL Stock Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avadel Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.66 |
| 52 Week High | US$18.85 |
| 52 Week Low | US$15.74 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.88% |
Recent News & Updates
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16
Recent updates
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05
Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years
Jan 10Avadel files US application for its lead drug
Dec 16Avadel's Xyrem Competitor: A Quick Overview
Dec 15Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Dec 15Shareholder Returns
| AVDL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.8% | 0.08% | 1.2% |
| 1Y | n/a | 13.2% | 24.9% |
Return vs Industry: Insufficient data to determine how AVDL performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AVDL performed against the US Market.
Price Volatility
| AVDL volatility | |
|---|---|
| AVDL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVDL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AVDL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 154 | Greg Divis | www.avadel.com |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc Fundamentals Summary
| AVDL fundamental statistics | |
|---|---|
| Market cap | US$1.64b |
| Earnings (TTM) | -US$160.28m |
| Revenue (TTM) | US$27.96m |
57.2x
P/S Ratio-10.0x
P/E RatioIs AVDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVDL income statement (TTM) | |
|---|---|
| Revenue | US$27.96m |
| Cost of Revenue | US$846.00k |
| Gross Profit | US$27.12m |
| Other Expenses | US$187.39m |
| Earnings | -US$160.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 96.97% |
| Net Profit Margin | -573.17% |
| Debt/Equity Ratio | 37.3% |
How did AVDL perform over the long term?
See historical performance and comparison